Investor Relations
Corporate identity strengthened
Since September 2009, Omega Pharma is using a new logo. Presently, preparations are ongoing to introduce this new logo in all countries where the company is operating. Whenever it is impossible or inappropriate to change the company name of a local subsidiary, the new logo will be implemented in a modified format (examples are shown at the right hand side). Over time, Omega Pharma intends to put this logo on all product packs, in all countries.
Omega Pharma sells 24.04% interest in Arseus
9 November 2009 (07:30 AM CET): Omega Pharma NV, Arseus NV and Waterland Private Equity Investments jointly announce today that Waterland has signed agreements to purchase a minority 25.10% interest in Arseus. Via its fourth fund, Waterland will purchase 7,500,000 shares (24.04%) from Omega Pharma and 330,000 shares (1.06%) from Couckinvest NV at €8 per Arseus share, plus an earn-out of up to €2.75 per share, payable when Waterland exits, depending on the future shareholder value created by Arseus. Completion of the transaction took place on 25 November 2009. The entire press release can be downloaded here.
IR presentation December 2009. Click here.
Click here for all available newsitems
